论文部分内容阅读
目的：比较华蟾素与阿昔洛韦治疗慢性乙型肝炎的疗效。方法：慢性乙型肝炎病人３７例，分华蟾素治疗组２３例（男性１４例，女性９例；年龄３２±ｓ８ａ）用华蟾素２０ｍＬ溶于１０％葡萄糖液５００ｍＬ中静脉缓滴，ｑｄ。阿昔洛韦对照组１４例（男性１１例，女性３例；年龄２７±７ａ）用阿昔洛韦７５０ｍｇ溶于复方氯化钠液５００ｍＬ中静脉缓滴，ｑｄ，疗程均为３０ｄ。结果：２组在改善病人临床症状、体征和肝功能方面效果均显著，华蟾素组与阿昔洛韦组的ＨＢｅＡｇ转阴率分别为４３％和４３％，ＨＢＶ－ＤＮＡ的转阴率分别为３９％和３６％，２组疗效无显著差异（Ｐ＞０．０５）。结论：华蟾素治疗慢性乙型肝炎的疗效与阿昔洛韦相似。
Objective: To compare the efficacy of cinobufacini and acyclovir in the treatment of chronic hepatitis B Methods: Thirty-seven patients with chronic hepatitis B and 23 patients with cinobufotalin (14 males and 9 females; age 32 ± s8a) were treated with 20 mL of Cinobufacini in 10 mL of 10% dextrose solution, . Acyclovir control group of 14 patients (11 males and 3 females; age 27 ± 7a) with acyclovir 750mg dissolved in 500mL sodium chloride solution in the middle of the intravenous drip, qd, treatment were 30d. Results: The two groups were effective in improving clinical symptoms, signs and liver function. The negative conversion rates of HBeAg in cinobufotalin group and acyclovir group were 43% and 43% respectively, and the negative conversion rate of HBV-DNA Was 39% and 36%, no significant difference between the two groups (P> 0.05). Conclusion: The efficacy of cinobufacini in the treatment of chronic hepatitis B is similar to acyclovir.